Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 6325999
Use of Fas ligand to suppress T-lymphocyte-mediated immune responses
expired -
US 6326198
Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
expired -
US 6326007
Attenuated lentivirus vectors expressing interferon
expired -
US 6326361
Gangliosides with immunosuppressive activity
expired -
US 6323226
Treatment of heart disease with cox-2 inhibitors
expired -
US 6323181
Antitumor agents
expired -
US 6323201
Compounds for inhibition of ceramide-mediated signal transduction
expired -
US 6323020
Neutralization-sensitive epitopes of Cryptosporidium parvum
expired -
US 6322802
Method of sterilizing
expired -
US 6323019
Design of novel highly efficient HIV based packaging systems for gene therapy
expired -
US 6323024
Coxsackie virus vectors for delivery of nucleic acids encoding antigenic or therapeutic products
expired -
US 6319495
Method for restoring glucose responsiveness to insulin secretion
expired -
US 6319521
Microparticles of lactide-co-glycolide copolymers and methods of making and using the same
expired -
US 6320027
Nucleotide sequence of the nucleocapsid gene of oropouche virus
expired -
US 6319900
Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs
expired -
US 6320037
IBD-associated microbial nucleic acid molecules
expired -
US 6316250
Molecular clones producing recombinant DNA antigens of the hantavirus-associated respiratory distress (HARDS)
expired -
US 6316601
Antibodies specific for .beta.6 integrins
expired -
US 6316421
Pentaerythritol lipid derivatives and nuleic-acid complexes
expired -
US 6312694
Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
expired -
US 6313115
Benzofurazan compounds which enhance AMPA receptor activity
expired -
US 6313178
Use of hexahydrolupulones as antibacterial and anticancer agents
expired -
US 6313155
Composition and method for treating macular disorders
expired -
US 6312664
Biodegradable contrast media for MR imaging
expired -
US 6309634
Methods of treating Parkinson's disease using recombinant adeno-associated vector (rAAV)
expired -
US 6310190
USPA1 and USPA2 antigens of Moraxella catarrhalis
expired -
US 6309867
Telomerase
expired -
US 6309651
Method of and compositions for immunization with the pseudomonas V antigen
expired -
US 6309854
Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
expired -
US 6309644
Parasitic nematode transglutaminase proteins and uses thereof
expired -
US 6309638
Netrins
expired -
US 6309352
Real time optoacoustic monitoring of changes in tissue properties
expired -
US 6309639
Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
expired -
US 6309643
IBD-associated microbial antigens and methods of using same
expired -
US 6307075
Therapeutically effective 1.alpha., 25-dihydroxyvitamin D3 analogs
expired -
US 6306830
Gene therapy for congestive heart failure
expired -
US 6306826
Treatment of heart failure with growth hormone
expired -
US 6306832
Peptide antiestrogen compositions and methods for treating breast cancer
expired -
US 6306623
Leptospiral major outer membrane protein LipL32
expired -
US 6306598
Nucleic acid-coupled colorimetric analyte detectors
expired -
US 6306922
Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
expired -
US 6303334
Nucleic acid encoding a transdominant negative retroviral integrase
expired -
US 6303331
Vertebrate apoptosis gene: compositions and methods
expired -
US 6303575
Indolicidin analogs and methods of using same
expired -
US 6300308
Methods and compositions for inducing autoimmunity in the treatment of cancers
expired -
US 6300470
Antibiotic cryptdin peptides and methods of their use
expired -
US 6300317
Self-assembling polynucleotide delivery system
expired -
US 6300111
Constitutively active phosphatidylinositol 3-kinase and uses thereof
expired
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory